User login
Live Streaming at CHEST 2017
In April 2016, Facebook launched Facebook Live, a tool for live streaming to a Facebook page to share live video with their followers on Facebook. At CHEST 2016, the CHEST New Media team began to experiment with live video with some early success. The CHEST 2017 team made the decision, based on the organization’s goal to help educate clinicians to improve patient care, to live stream complete sessions from CHEST 2017. With the help of the CHEST 2017 Education Committee and the Social Media Work Group, more than 25 sessions were selected and live streamed.
CHEST’s efforts on Facebook Live resulted in the following:
- Total people reached: 133,737
- Total video views: 34,449
- Total minutes watched: 30,786 (or 513 hours, or 21 days)
- Total interactions: 1,050 (eg, likes, loves, hahas, etc)
- Total shares: 302
The content concept was well received, and comments ranged from followers chiming in with their location, appreciation for live streaming, and even comments from patients.
- “Thank you for sharing this live presentation.”
- “Here from Mexico !!”
- “Here from Natal/RN, Brazil”
- “Here from Milan, Italy.”
- “Appreciate this live streaming on important sessions, big service for those who couldn’t attend!!”
- “My brother survived after six days on ECMO. I am so glad to have him.”
- “It’s a great chance for physicians working in pulmonology and general practice to get the pearls of guidelines from American College to improve clinical practice. Now distance doesn’t matter”
Plans are underway for live streaming from CHEST 2018 in San Antonio. To view the CHEST 2017 live stream videos, visit CHEST’s Facebook page, facebook.com/accpchest.
In April 2016, Facebook launched Facebook Live, a tool for live streaming to a Facebook page to share live video with their followers on Facebook. At CHEST 2016, the CHEST New Media team began to experiment with live video with some early success. The CHEST 2017 team made the decision, based on the organization’s goal to help educate clinicians to improve patient care, to live stream complete sessions from CHEST 2017. With the help of the CHEST 2017 Education Committee and the Social Media Work Group, more than 25 sessions were selected and live streamed.
CHEST’s efforts on Facebook Live resulted in the following:
- Total people reached: 133,737
- Total video views: 34,449
- Total minutes watched: 30,786 (or 513 hours, or 21 days)
- Total interactions: 1,050 (eg, likes, loves, hahas, etc)
- Total shares: 302
The content concept was well received, and comments ranged from followers chiming in with their location, appreciation for live streaming, and even comments from patients.
- “Thank you for sharing this live presentation.”
- “Here from Mexico !!”
- “Here from Natal/RN, Brazil”
- “Here from Milan, Italy.”
- “Appreciate this live streaming on important sessions, big service for those who couldn’t attend!!”
- “My brother survived after six days on ECMO. I am so glad to have him.”
- “It’s a great chance for physicians working in pulmonology and general practice to get the pearls of guidelines from American College to improve clinical practice. Now distance doesn’t matter”
Plans are underway for live streaming from CHEST 2018 in San Antonio. To view the CHEST 2017 live stream videos, visit CHEST’s Facebook page, facebook.com/accpchest.
In April 2016, Facebook launched Facebook Live, a tool for live streaming to a Facebook page to share live video with their followers on Facebook. At CHEST 2016, the CHEST New Media team began to experiment with live video with some early success. The CHEST 2017 team made the decision, based on the organization’s goal to help educate clinicians to improve patient care, to live stream complete sessions from CHEST 2017. With the help of the CHEST 2017 Education Committee and the Social Media Work Group, more than 25 sessions were selected and live streamed.
CHEST’s efforts on Facebook Live resulted in the following:
- Total people reached: 133,737
- Total video views: 34,449
- Total minutes watched: 30,786 (or 513 hours, or 21 days)
- Total interactions: 1,050 (eg, likes, loves, hahas, etc)
- Total shares: 302
The content concept was well received, and comments ranged from followers chiming in with their location, appreciation for live streaming, and even comments from patients.
- “Thank you for sharing this live presentation.”
- “Here from Mexico !!”
- “Here from Natal/RN, Brazil”
- “Here from Milan, Italy.”
- “Appreciate this live streaming on important sessions, big service for those who couldn’t attend!!”
- “My brother survived after six days on ECMO. I am so glad to have him.”
- “It’s a great chance for physicians working in pulmonology and general practice to get the pearls of guidelines from American College to improve clinical practice. Now distance doesn’t matter”
Plans are underway for live streaming from CHEST 2018 in San Antonio. To view the CHEST 2017 live stream videos, visit CHEST’s Facebook page, facebook.com/accpchest.
This Month in CHEST® Editor’s Picks
Editorial
Introducing the CHEST Teaching, Education, and Career Hub
Dr. G. T. Bosslet and Dr. M. Miles
Training, Education, and Career Hub - TEaCH
Dr. R. W. Ashton, et al.
Commentary
Higher Priced Older Pharmaceuticals: How Should We Respond?
Dr. R. S. Irwin, et al.
Giants in Chest Medicine
Jeffrey M. Drazen, MD, FCCP
Dr. A. S. Slutsky
Dr. R. S. Irwin, et al.
Original Research
Three-Hour Bundle Compliance and Outcomes in Patients With Undiagnosed Severe Sepsis
Dr. A. S. Deis, et al.
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
Dr. I. O. Rosas, et al.
Editorial
Introducing the CHEST Teaching, Education, and Career Hub
Dr. G. T. Bosslet and Dr. M. Miles
Training, Education, and Career Hub - TEaCH
Dr. R. W. Ashton, et al.
Commentary
Higher Priced Older Pharmaceuticals: How Should We Respond?
Dr. R. S. Irwin, et al.
Giants in Chest Medicine
Jeffrey M. Drazen, MD, FCCP
Dr. A. S. Slutsky
Dr. R. S. Irwin, et al.
Original Research
Three-Hour Bundle Compliance and Outcomes in Patients With Undiagnosed Severe Sepsis
Dr. A. S. Deis, et al.
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
Dr. I. O. Rosas, et al.
Editorial
Introducing the CHEST Teaching, Education, and Career Hub
Dr. G. T. Bosslet and Dr. M. Miles
Training, Education, and Career Hub - TEaCH
Dr. R. W. Ashton, et al.
Commentary
Higher Priced Older Pharmaceuticals: How Should We Respond?
Dr. R. S. Irwin, et al.
Giants in Chest Medicine
Jeffrey M. Drazen, MD, FCCP
Dr. A. S. Slutsky
Dr. R. S. Irwin, et al.
Original Research
Three-Hour Bundle Compliance and Outcomes in Patients With Undiagnosed Severe Sepsis
Dr. A. S. Deis, et al.
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
Dr. I. O. Rosas, et al.
Another Small Win to Raise the Tobacco Purchasing Age to 21
The Elk Grove Village, Illinois, Board of Trustees passed the “Tobacco 21” ordinance that will raise the tobacco purchasing age to 21, which includes nicotine vaping. The policy, which will go into effect January 1, 2018, will protect young people from beginning a lifetime of addiction and, ultimately, save their lives.
Kevin L Kovitz MD, MBA, FCCP, attended the Village Board meeting to advocate for “Tobacco 21.” He is a Sustaining Member of the CHEST Foundation, continually exemplifying what it is to be a lung health champion.
Dr. Kovitz noted, “This policy will protect our kids from the scourge of Big Tobacco and save funding for health-care costs and, most importantly, will ultimately save lives. The ordinance will protect the most vulnerable parts of our population, our children. Raising the legal age puts tobacco products on par with alcohol and protects young adults from developing a dangerous lifelong habit.”
Five US states have also passed Tobacco 21; they include California, Hawaii, Maine, New Jersey, and Oregon. There are many local ordinances around the country but more are needed.
Advocating for this ordinance demonstrates the effectiveness of grassroots advocacy in our local communities.
The Elk Grove Village, Illinois, Board of Trustees passed the “Tobacco 21” ordinance that will raise the tobacco purchasing age to 21, which includes nicotine vaping. The policy, which will go into effect January 1, 2018, will protect young people from beginning a lifetime of addiction and, ultimately, save their lives.
Kevin L Kovitz MD, MBA, FCCP, attended the Village Board meeting to advocate for “Tobacco 21.” He is a Sustaining Member of the CHEST Foundation, continually exemplifying what it is to be a lung health champion.
Dr. Kovitz noted, “This policy will protect our kids from the scourge of Big Tobacco and save funding for health-care costs and, most importantly, will ultimately save lives. The ordinance will protect the most vulnerable parts of our population, our children. Raising the legal age puts tobacco products on par with alcohol and protects young adults from developing a dangerous lifelong habit.”
Five US states have also passed Tobacco 21; they include California, Hawaii, Maine, New Jersey, and Oregon. There are many local ordinances around the country but more are needed.
Advocating for this ordinance demonstrates the effectiveness of grassroots advocacy in our local communities.
The Elk Grove Village, Illinois, Board of Trustees passed the “Tobacco 21” ordinance that will raise the tobacco purchasing age to 21, which includes nicotine vaping. The policy, which will go into effect January 1, 2018, will protect young people from beginning a lifetime of addiction and, ultimately, save their lives.
Kevin L Kovitz MD, MBA, FCCP, attended the Village Board meeting to advocate for “Tobacco 21.” He is a Sustaining Member of the CHEST Foundation, continually exemplifying what it is to be a lung health champion.
Dr. Kovitz noted, “This policy will protect our kids from the scourge of Big Tobacco and save funding for health-care costs and, most importantly, will ultimately save lives. The ordinance will protect the most vulnerable parts of our population, our children. Raising the legal age puts tobacco products on par with alcohol and protects young adults from developing a dangerous lifelong habit.”
Five US states have also passed Tobacco 21; they include California, Hawaii, Maine, New Jersey, and Oregon. There are many local ordinances around the country but more are needed.
Advocating for this ordinance demonstrates the effectiveness of grassroots advocacy in our local communities.
BP targets questioned, Candida auris infections
Cardiovascular Medicine and Surgery
The Holy Grail of Blood Pressure Management?
Blood pressure treatment recommendations have been confusing over the past few years. The Joint National Committee (JNC) 8 stirred up controversy in 2014 because they raised the recommended tolerating systolic blood pressures, in certain people aged 60 and above, up to 150 mm Hg [James, et al. JAMA. 2014;311(5):507-520]. The new AHA/ACC hypertension guidelines cosponsored by 11 societies generated controversy because they changed the definition of hypertension (normal <120/80 mm Hg, elevated 120-129/80-89, stage 1 130-139/80-89, or stage 2 >140/90) [Whelton et al. J Am Coll Cardiol. 2017 pii:S0735-1097(17)41519-1]. The SPRINT trial [Wright, et al. N Engl J Med. 2015;373:2103-2116] largely influenced these recommendations. SPRINT demonstrated a 25% relative risk reduction of heart attack, stroke, cardiovascular death, or decompensated heart failure with more aggressive blood pressure management (BP goal <120/90 vs <140/90).
This new classification would label 46% of Americans, or 103.3 million people, as hypertensive. However, there is uncertainty in how broadly applicable the SPRINT results are, particularly in those under the age of 45. The majority of large clinical trials, including SPRINT, have limited numbers of patients who were less than 50 years old and, therefore, it is unknown if younger patients benefit to the same degree. The absolute improvement is also questionable because as an editorial points out [Welch, “Don’t Let New Blood Pressure Guidelines Raise Yours” NY Times. Nov. 15, 2017], the primary endpoint in SPRINT only occurred in less than or equal to 8% of patients.
These guidelines reinforce the need to measure ambulatory blood pressures, perform proper in-office blood pressure measurements, and emphasize lifestyle modifications. Whether aggressive blood pressure management is worth the potential risks and the degree to which ideal blood pressure measurement can be applied to real world practices, remains uncertain.
David J. Nagel, MD, PhD Steering Committee Member
Chest Infections
Candida auris
Invasive fungal infections are frequently managed by ICU physicians and are a leading cause of mortality among critically ill patients. Invasive candidiasis is associated with an attributable mortality rate of up to 49%. Historically, the majority of these infections has been caused by Candida albicans, but this may be changing.
The first outbreak of Candida auris in the Americas (18 patients) occurred in the ICU of a hospital in Venezuela. Resistance to common azoles was documented, and half of the isolates showed decreased susceptibility to amphotericin B. As of August 2017, a total 153 clinical cases of C auris infection have been reported to CDC from 10 US states; most have occurred in New York and New Jersey.
What has been learned from these cases is that close contacts can be colonized, colonization can be persistent (approximately 9 months), the yeast can survive in the hospital environment, bleach or sporicide is needed for elimination, isolation precautions are recommended as for MDRO bacteria, and serial resistance to echinocandins has been observed.
Principal takeaways:
1Candida auris isolates are often MDR, with some strains having elevated MICs to drugs in all the three major classes of antifungal medications.
2The isolates are difficult to identify and require specialized methods, such as MALDI-TOF or molecular identification based on sequencing.
3Misidentification may lead to inappropriate treatment.
4C auris has the propensity to cause outbreaks in health-care settings, as has been reported in several countries, and resistance may result in treatment failure.
Richard Winn, MD, MS, FCCPImmediate Past Chair
References
1. Sarma S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resistance. 2017;10:155–165.
2. Pan American Health Organization/World Health Organization. Epidemiological Alert: Candida auris outbreaks in health care services. October 3, Washington, DC: PAHO/WHO; 2016.
3. Centers for Disease Control and Prevention. Global emergence of invasive infections caused by the multidrug-resistant yeast Candida auris. CDC; 2016 [updated June 24, 2016]
Cardiovascular Medicine and Surgery
The Holy Grail of Blood Pressure Management?
Blood pressure treatment recommendations have been confusing over the past few years. The Joint National Committee (JNC) 8 stirred up controversy in 2014 because they raised the recommended tolerating systolic blood pressures, in certain people aged 60 and above, up to 150 mm Hg [James, et al. JAMA. 2014;311(5):507-520]. The new AHA/ACC hypertension guidelines cosponsored by 11 societies generated controversy because they changed the definition of hypertension (normal <120/80 mm Hg, elevated 120-129/80-89, stage 1 130-139/80-89, or stage 2 >140/90) [Whelton et al. J Am Coll Cardiol. 2017 pii:S0735-1097(17)41519-1]. The SPRINT trial [Wright, et al. N Engl J Med. 2015;373:2103-2116] largely influenced these recommendations. SPRINT demonstrated a 25% relative risk reduction of heart attack, stroke, cardiovascular death, or decompensated heart failure with more aggressive blood pressure management (BP goal <120/90 vs <140/90).
This new classification would label 46% of Americans, or 103.3 million people, as hypertensive. However, there is uncertainty in how broadly applicable the SPRINT results are, particularly in those under the age of 45. The majority of large clinical trials, including SPRINT, have limited numbers of patients who were less than 50 years old and, therefore, it is unknown if younger patients benefit to the same degree. The absolute improvement is also questionable because as an editorial points out [Welch, “Don’t Let New Blood Pressure Guidelines Raise Yours” NY Times. Nov. 15, 2017], the primary endpoint in SPRINT only occurred in less than or equal to 8% of patients.
These guidelines reinforce the need to measure ambulatory blood pressures, perform proper in-office blood pressure measurements, and emphasize lifestyle modifications. Whether aggressive blood pressure management is worth the potential risks and the degree to which ideal blood pressure measurement can be applied to real world practices, remains uncertain.
David J. Nagel, MD, PhD Steering Committee Member
Chest Infections
Candida auris
Invasive fungal infections are frequently managed by ICU physicians and are a leading cause of mortality among critically ill patients. Invasive candidiasis is associated with an attributable mortality rate of up to 49%. Historically, the majority of these infections has been caused by Candida albicans, but this may be changing.
The first outbreak of Candida auris in the Americas (18 patients) occurred in the ICU of a hospital in Venezuela. Resistance to common azoles was documented, and half of the isolates showed decreased susceptibility to amphotericin B. As of August 2017, a total 153 clinical cases of C auris infection have been reported to CDC from 10 US states; most have occurred in New York and New Jersey.
What has been learned from these cases is that close contacts can be colonized, colonization can be persistent (approximately 9 months), the yeast can survive in the hospital environment, bleach or sporicide is needed for elimination, isolation precautions are recommended as for MDRO bacteria, and serial resistance to echinocandins has been observed.
Principal takeaways:
1Candida auris isolates are often MDR, with some strains having elevated MICs to drugs in all the three major classes of antifungal medications.
2The isolates are difficult to identify and require specialized methods, such as MALDI-TOF or molecular identification based on sequencing.
3Misidentification may lead to inappropriate treatment.
4C auris has the propensity to cause outbreaks in health-care settings, as has been reported in several countries, and resistance may result in treatment failure.
Richard Winn, MD, MS, FCCPImmediate Past Chair
References
1. Sarma S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resistance. 2017;10:155–165.
2. Pan American Health Organization/World Health Organization. Epidemiological Alert: Candida auris outbreaks in health care services. October 3, Washington, DC: PAHO/WHO; 2016.
3. Centers for Disease Control and Prevention. Global emergence of invasive infections caused by the multidrug-resistant yeast Candida auris. CDC; 2016 [updated June 24, 2016]
Cardiovascular Medicine and Surgery
The Holy Grail of Blood Pressure Management?
Blood pressure treatment recommendations have been confusing over the past few years. The Joint National Committee (JNC) 8 stirred up controversy in 2014 because they raised the recommended tolerating systolic blood pressures, in certain people aged 60 and above, up to 150 mm Hg [James, et al. JAMA. 2014;311(5):507-520]. The new AHA/ACC hypertension guidelines cosponsored by 11 societies generated controversy because they changed the definition of hypertension (normal <120/80 mm Hg, elevated 120-129/80-89, stage 1 130-139/80-89, or stage 2 >140/90) [Whelton et al. J Am Coll Cardiol. 2017 pii:S0735-1097(17)41519-1]. The SPRINT trial [Wright, et al. N Engl J Med. 2015;373:2103-2116] largely influenced these recommendations. SPRINT demonstrated a 25% relative risk reduction of heart attack, stroke, cardiovascular death, or decompensated heart failure with more aggressive blood pressure management (BP goal <120/90 vs <140/90).
This new classification would label 46% of Americans, or 103.3 million people, as hypertensive. However, there is uncertainty in how broadly applicable the SPRINT results are, particularly in those under the age of 45. The majority of large clinical trials, including SPRINT, have limited numbers of patients who were less than 50 years old and, therefore, it is unknown if younger patients benefit to the same degree. The absolute improvement is also questionable because as an editorial points out [Welch, “Don’t Let New Blood Pressure Guidelines Raise Yours” NY Times. Nov. 15, 2017], the primary endpoint in SPRINT only occurred in less than or equal to 8% of patients.
These guidelines reinforce the need to measure ambulatory blood pressures, perform proper in-office blood pressure measurements, and emphasize lifestyle modifications. Whether aggressive blood pressure management is worth the potential risks and the degree to which ideal blood pressure measurement can be applied to real world practices, remains uncertain.
David J. Nagel, MD, PhD Steering Committee Member
Chest Infections
Candida auris
Invasive fungal infections are frequently managed by ICU physicians and are a leading cause of mortality among critically ill patients. Invasive candidiasis is associated with an attributable mortality rate of up to 49%. Historically, the majority of these infections has been caused by Candida albicans, but this may be changing.
The first outbreak of Candida auris in the Americas (18 patients) occurred in the ICU of a hospital in Venezuela. Resistance to common azoles was documented, and half of the isolates showed decreased susceptibility to amphotericin B. As of August 2017, a total 153 clinical cases of C auris infection have been reported to CDC from 10 US states; most have occurred in New York and New Jersey.
What has been learned from these cases is that close contacts can be colonized, colonization can be persistent (approximately 9 months), the yeast can survive in the hospital environment, bleach or sporicide is needed for elimination, isolation precautions are recommended as for MDRO bacteria, and serial resistance to echinocandins has been observed.
Principal takeaways:
1Candida auris isolates are often MDR, with some strains having elevated MICs to drugs in all the three major classes of antifungal medications.
2The isolates are difficult to identify and require specialized methods, such as MALDI-TOF or molecular identification based on sequencing.
3Misidentification may lead to inappropriate treatment.
4C auris has the propensity to cause outbreaks in health-care settings, as has been reported in several countries, and resistance may result in treatment failure.
Richard Winn, MD, MS, FCCPImmediate Past Chair
References
1. Sarma S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resistance. 2017;10:155–165.
2. Pan American Health Organization/World Health Organization. Epidemiological Alert: Candida auris outbreaks in health care services. October 3, Washington, DC: PAHO/WHO; 2016.
3. Centers for Disease Control and Prevention. Global emergence of invasive infections caused by the multidrug-resistant yeast Candida auris. CDC; 2016 [updated June 24, 2016]
New CHEST Physician Leadership for 2018
David A. Schulman, MD, FCCP, is the new Editor in Chief of CHEST Physician. He is a Professor in the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine at Emory University in Atlanta, where he also directs the pulmonary and critical care fellowship program. He has served on the CHEST Sleep NetWork and the Education Committee and currently serves on the Training and Transitions Committee and the Board of Regents. Dr. Schulman’s primary area of academic interest is on faculty development in the domains of teaching and assessment. He will serve as the Chair of the CHEST 2018 Scientific Program Committee, where he will focus on crafting novel, interactive programming that will improve attendee engagement and retention.
1. Improve interactivity between CHEST Physician and its readership, to improve our ability to craft the publication that best meets the needs of its readers.
2. Create more opportunities for CHEST Physician to serve as the voice of CHEST members, by increasing space for members and leaders to write for the publication.
3. Build on the incredibly successful work of my predecessor, Dr. Vera DePalo.
CHEST extends very special thanks to the following CHEST Physician editors for their 3 years of dedicated service in the following roles:
Vera de Palo, MD, FCCP – Editor in Chief
Lee Morrow, MD, FCCP – Section Editor for Critical Care Commentary
Jeremy Weingarten, MD, FCCP – Section Editor for Sleep Strategies
David A. Schulman, MD, FCCP, is the new Editor in Chief of CHEST Physician. He is a Professor in the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine at Emory University in Atlanta, where he also directs the pulmonary and critical care fellowship program. He has served on the CHEST Sleep NetWork and the Education Committee and currently serves on the Training and Transitions Committee and the Board of Regents. Dr. Schulman’s primary area of academic interest is on faculty development in the domains of teaching and assessment. He will serve as the Chair of the CHEST 2018 Scientific Program Committee, where he will focus on crafting novel, interactive programming that will improve attendee engagement and retention.
1. Improve interactivity between CHEST Physician and its readership, to improve our ability to craft the publication that best meets the needs of its readers.
2. Create more opportunities for CHEST Physician to serve as the voice of CHEST members, by increasing space for members and leaders to write for the publication.
3. Build on the incredibly successful work of my predecessor, Dr. Vera DePalo.
CHEST extends very special thanks to the following CHEST Physician editors for their 3 years of dedicated service in the following roles:
Vera de Palo, MD, FCCP – Editor in Chief
Lee Morrow, MD, FCCP – Section Editor for Critical Care Commentary
Jeremy Weingarten, MD, FCCP – Section Editor for Sleep Strategies
David A. Schulman, MD, FCCP, is the new Editor in Chief of CHEST Physician. He is a Professor in the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine at Emory University in Atlanta, where he also directs the pulmonary and critical care fellowship program. He has served on the CHEST Sleep NetWork and the Education Committee and currently serves on the Training and Transitions Committee and the Board of Regents. Dr. Schulman’s primary area of academic interest is on faculty development in the domains of teaching and assessment. He will serve as the Chair of the CHEST 2018 Scientific Program Committee, where he will focus on crafting novel, interactive programming that will improve attendee engagement and retention.
1. Improve interactivity between CHEST Physician and its readership, to improve our ability to craft the publication that best meets the needs of its readers.
2. Create more opportunities for CHEST Physician to serve as the voice of CHEST members, by increasing space for members and leaders to write for the publication.
3. Build on the incredibly successful work of my predecessor, Dr. Vera DePalo.
CHEST extends very special thanks to the following CHEST Physician editors for their 3 years of dedicated service in the following roles:
Vera de Palo, MD, FCCP – Editor in Chief
Lee Morrow, MD, FCCP – Section Editor for Critical Care Commentary
Jeremy Weingarten, MD, FCCP – Section Editor for Sleep Strategies
News From American Association of Critical-Care Nurses (AACN)
AACN has published a new edition of “AACN Scope and Standards for Acute Care Nurse Practitioner Practice” to reflect the specialty’s evolving role and an ever-changing critical care landscape.
First issued in 2006 and previously updated in 2012, the new edition describes and measures the expected level of practice and professional performance for acute care nurse practitioners (ACNPs). The 2017 edition, which came from collaboration from a work group of ACNP subject matter experts convened by AACN collaborated to update the content to reflect current practice incorporates advances in scientific knowledge, clinical practice, technology and other changes in the dynamic healthcare environment. It addresses the full scope of practice for ACNPs, including those whose education and training prepare them to care for children with acute and critical illnesses. It also aligns with the “Consensus Model for APRN Regulation” — also called the LACE Model — developed to create national congruence for licensure, accreditation, certification, and education of advanced practice nurses.
“The role of acute care nurse practitioners continues to expand as more hospitals and healthcare organizations discover the value of having ACNPs on staff,” said Linda Bell, AACN clinical practice specialist and editor of the publication. “Patients who used to be hospitalized are now cared for throughout the healthcare system. As a result, the services or care provided by ACNPs and other advanced practice providers are not defined or limited by setting but rather by patient care needs.”
These standards are a valuable resource for acute care pediatric nurse practitioners (CPNP-AC), adult ACNPs (ACNPC-AG or ACNP-BC) and those developing educational programs for advanced nursing practice, job descriptions and credentialing, among other uses.
New edition of ACNP Scope and Standard is available from American Association of Critical-Care Nurses (aacn.org).
AACN has published a new edition of “AACN Scope and Standards for Acute Care Nurse Practitioner Practice” to reflect the specialty’s evolving role and an ever-changing critical care landscape.
First issued in 2006 and previously updated in 2012, the new edition describes and measures the expected level of practice and professional performance for acute care nurse practitioners (ACNPs). The 2017 edition, which came from collaboration from a work group of ACNP subject matter experts convened by AACN collaborated to update the content to reflect current practice incorporates advances in scientific knowledge, clinical practice, technology and other changes in the dynamic healthcare environment. It addresses the full scope of practice for ACNPs, including those whose education and training prepare them to care for children with acute and critical illnesses. It also aligns with the “Consensus Model for APRN Regulation” — also called the LACE Model — developed to create national congruence for licensure, accreditation, certification, and education of advanced practice nurses.
“The role of acute care nurse practitioners continues to expand as more hospitals and healthcare organizations discover the value of having ACNPs on staff,” said Linda Bell, AACN clinical practice specialist and editor of the publication. “Patients who used to be hospitalized are now cared for throughout the healthcare system. As a result, the services or care provided by ACNPs and other advanced practice providers are not defined or limited by setting but rather by patient care needs.”
These standards are a valuable resource for acute care pediatric nurse practitioners (CPNP-AC), adult ACNPs (ACNPC-AG or ACNP-BC) and those developing educational programs for advanced nursing practice, job descriptions and credentialing, among other uses.
New edition of ACNP Scope and Standard is available from American Association of Critical-Care Nurses (aacn.org).
AACN has published a new edition of “AACN Scope and Standards for Acute Care Nurse Practitioner Practice” to reflect the specialty’s evolving role and an ever-changing critical care landscape.
First issued in 2006 and previously updated in 2012, the new edition describes and measures the expected level of practice and professional performance for acute care nurse practitioners (ACNPs). The 2017 edition, which came from collaboration from a work group of ACNP subject matter experts convened by AACN collaborated to update the content to reflect current practice incorporates advances in scientific knowledge, clinical practice, technology and other changes in the dynamic healthcare environment. It addresses the full scope of practice for ACNPs, including those whose education and training prepare them to care for children with acute and critical illnesses. It also aligns with the “Consensus Model for APRN Regulation” — also called the LACE Model — developed to create national congruence for licensure, accreditation, certification, and education of advanced practice nurses.
“The role of acute care nurse practitioners continues to expand as more hospitals and healthcare organizations discover the value of having ACNPs on staff,” said Linda Bell, AACN clinical practice specialist and editor of the publication. “Patients who used to be hospitalized are now cared for throughout the healthcare system. As a result, the services or care provided by ACNPs and other advanced practice providers are not defined or limited by setting but rather by patient care needs.”
These standards are a valuable resource for acute care pediatric nurse practitioners (CPNP-AC), adult ACNPs (ACNPC-AG or ACNP-BC) and those developing educational programs for advanced nursing practice, job descriptions and credentialing, among other uses.
New edition of ACNP Scope and Standard is available from American Association of Critical-Care Nurses (aacn.org).
CHEST President, Dr. John Studdard on the Search for a New Editor in Chief for CHEST®
CHEST®, the flagship peer-reviewed journal of the American College of Chest Physicians (CHEST), is seeking applicants for the next Editor in Chief (EIC). President of CHEST, Dr. John Studdard, has given some insight into the successes of the journal during current EIC, Dr. Richard Irwin’s tenure, and what we can expect from the respected individual who will take his place in 2019.
“From my perspective as a community-based physician practicing pulmonary, critical care, and sleep medicine, I believe the responsibility of member-based organizations like CHEST is to ensure that we create meaningful science, create outstanding education, and work to ensure these are disseminated and implemented. One of the most important vehicles that we depend on is our CHEST® journal.
CHEST® is more than just a medical journal; it is the face and brand of the American College of Chest Physicians. Recognition and awareness of the journal as the face of the organization is an incredibly important aspect of what it means to the CHEST organization as a whole.”
Dr. Studdard’s insights as to some of the successes and the future of CHEST®:
Question: What is your view on the successes of the journal over Dr. Irwin’s tenure?
Answer: A. The journal consistently ranks as the #1 relevant journal for respiratory clinicians and providers.
B. The journal’s “impact factor” has increased significantly, which supports its efforts to attract the best clinical research and content.
C. New sections added provide applicable clinical information, address hot and controversial topics, and underscore the human side of medicine to support the best patient-focused care.
D. The continual improvement of our online platform, including development of multimedia content and other innovations that take advantage of the digital evolution of online content delivery.
E. Last, but not least, I believe our members who are clinicians consider CHEST® to be the one journal to review cover to cover and to be their “go to” journal for relevant clinical insights and information.
Question: What challenges does CHEST expect the next EIC to be facing?
Answer: We clearly practice in an environment where there are constant pulls for the time and attention of clinicians … a constant influx of information and education in multiple formats and delivery systems. The journal CHEST® must highlight the information we need most that will impact patient care. Our new EIC, and the team assembled, will need to solicit the best research, continue our digital evolution, and ensure they are delivering this information in the way that our members and learners find the most accessible.Question: Where do “we” want the journal to go?
Answer: Your leadership of the American College of Chest Physicians has great respect for the editorial independence of the journal. The EIC and the Editorial Board that is assembled will lead where the journal goes. As the embodiment of the brand of the CHEST organization, we clearly want to see the journal continue to be the authoritative, respected, trusted, “go to” resource for clinical pulmonary, critical care, and sleep medicine professionals.
CHEST is now accepting applications for the position of Editor in Chief of the CHEST® journal. For more information visit http://info.chestnet.org/editor-in-chief. Applications are due by February 1, 2018.
CHEST®, the flagship peer-reviewed journal of the American College of Chest Physicians (CHEST), is seeking applicants for the next Editor in Chief (EIC). President of CHEST, Dr. John Studdard, has given some insight into the successes of the journal during current EIC, Dr. Richard Irwin’s tenure, and what we can expect from the respected individual who will take his place in 2019.
“From my perspective as a community-based physician practicing pulmonary, critical care, and sleep medicine, I believe the responsibility of member-based organizations like CHEST is to ensure that we create meaningful science, create outstanding education, and work to ensure these are disseminated and implemented. One of the most important vehicles that we depend on is our CHEST® journal.
CHEST® is more than just a medical journal; it is the face and brand of the American College of Chest Physicians. Recognition and awareness of the journal as the face of the organization is an incredibly important aspect of what it means to the CHEST organization as a whole.”
Dr. Studdard’s insights as to some of the successes and the future of CHEST®:
Question: What is your view on the successes of the journal over Dr. Irwin’s tenure?
Answer: A. The journal consistently ranks as the #1 relevant journal for respiratory clinicians and providers.
B. The journal’s “impact factor” has increased significantly, which supports its efforts to attract the best clinical research and content.
C. New sections added provide applicable clinical information, address hot and controversial topics, and underscore the human side of medicine to support the best patient-focused care.
D. The continual improvement of our online platform, including development of multimedia content and other innovations that take advantage of the digital evolution of online content delivery.
E. Last, but not least, I believe our members who are clinicians consider CHEST® to be the one journal to review cover to cover and to be their “go to” journal for relevant clinical insights and information.
Question: What challenges does CHEST expect the next EIC to be facing?
Answer: We clearly practice in an environment where there are constant pulls for the time and attention of clinicians … a constant influx of information and education in multiple formats and delivery systems. The journal CHEST® must highlight the information we need most that will impact patient care. Our new EIC, and the team assembled, will need to solicit the best research, continue our digital evolution, and ensure they are delivering this information in the way that our members and learners find the most accessible.Question: Where do “we” want the journal to go?
Answer: Your leadership of the American College of Chest Physicians has great respect for the editorial independence of the journal. The EIC and the Editorial Board that is assembled will lead where the journal goes. As the embodiment of the brand of the CHEST organization, we clearly want to see the journal continue to be the authoritative, respected, trusted, “go to” resource for clinical pulmonary, critical care, and sleep medicine professionals.
CHEST is now accepting applications for the position of Editor in Chief of the CHEST® journal. For more information visit http://info.chestnet.org/editor-in-chief. Applications are due by February 1, 2018.
CHEST®, the flagship peer-reviewed journal of the American College of Chest Physicians (CHEST), is seeking applicants for the next Editor in Chief (EIC). President of CHEST, Dr. John Studdard, has given some insight into the successes of the journal during current EIC, Dr. Richard Irwin’s tenure, and what we can expect from the respected individual who will take his place in 2019.
“From my perspective as a community-based physician practicing pulmonary, critical care, and sleep medicine, I believe the responsibility of member-based organizations like CHEST is to ensure that we create meaningful science, create outstanding education, and work to ensure these are disseminated and implemented. One of the most important vehicles that we depend on is our CHEST® journal.
CHEST® is more than just a medical journal; it is the face and brand of the American College of Chest Physicians. Recognition and awareness of the journal as the face of the organization is an incredibly important aspect of what it means to the CHEST organization as a whole.”
Dr. Studdard’s insights as to some of the successes and the future of CHEST®:
Question: What is your view on the successes of the journal over Dr. Irwin’s tenure?
Answer: A. The journal consistently ranks as the #1 relevant journal for respiratory clinicians and providers.
B. The journal’s “impact factor” has increased significantly, which supports its efforts to attract the best clinical research and content.
C. New sections added provide applicable clinical information, address hot and controversial topics, and underscore the human side of medicine to support the best patient-focused care.
D. The continual improvement of our online platform, including development of multimedia content and other innovations that take advantage of the digital evolution of online content delivery.
E. Last, but not least, I believe our members who are clinicians consider CHEST® to be the one journal to review cover to cover and to be their “go to” journal for relevant clinical insights and information.
Question: What challenges does CHEST expect the next EIC to be facing?
Answer: We clearly practice in an environment where there are constant pulls for the time and attention of clinicians … a constant influx of information and education in multiple formats and delivery systems. The journal CHEST® must highlight the information we need most that will impact patient care. Our new EIC, and the team assembled, will need to solicit the best research, continue our digital evolution, and ensure they are delivering this information in the way that our members and learners find the most accessible.Question: Where do “we” want the journal to go?
Answer: Your leadership of the American College of Chest Physicians has great respect for the editorial independence of the journal. The EIC and the Editorial Board that is assembled will lead where the journal goes. As the embodiment of the brand of the CHEST organization, we clearly want to see the journal continue to be the authoritative, respected, trusted, “go to” resource for clinical pulmonary, critical care, and sleep medicine professionals.
CHEST is now accepting applications for the position of Editor in Chief of the CHEST® journal. For more information visit http://info.chestnet.org/editor-in-chief. Applications are due by February 1, 2018.
Winners-All at CHEST 2017
With the great success of CHEST 2017, everyone who shared that event is a winner. But, we would especially like to call out some of the special winners who were recognized during our meeting in Toronto.
CHEST 2017 Awards
- College Medalist Award Sidney Braman, MD, Master FCCP
- Distinguished Service Award Nancy Collop, MD, FCCP
- Master FCCP Suhail Raoof, MD, Master FCCP
- Master FCCP Sidney Braman, MD, Master FCCP
- Early Career Clinician Educator Septimiu Murgu, MD, FCCP
- Master Clinician Educator Stephanie Levine, MD, FCCP
- Presidential Citation Sanjeev Mehta, MD, FCCP
- Presidential Citation Lisa Moores, MD, FCCP
- Alfred Soffer Award for Editorial Excellence Christopher Carroll, MD, FCCPDeep Ramachandran, MBBS
Honor Lectures
- Thomas L. Petty, MD, Master FCCP Memorial Lecture Personalized Treatment in COPD: A New Era of Treatment OptionsGerard J. Criner, MD, FCCP
- Presidential Honor Lecture Passion, Perseverance, and Quantum Leaps: Major Advances in Lung Cancer CareM. Patricia Rivera, MD, FCCP
- Margaret Pfrommer Memorial Lecture in Long-term Mechanical Ventilation When Air becomes BREATH…and a LIFE worth living Audrey King, MA
- Distinguished Scientist Honor Lecture in Cardiopulmonary Physiology Sleep, Death and the HeartVirend K. Somers, MD, PhD, FCCP
- Pasquale Ciaglia Memorial Lecture in Interventional Medicine Augmented Reality: Getting Real in Procedural EducationCarla R. Lamb, MD, FCCP
- Roger C. Bone Memorial Lecture in Critical Care If You’ve Seen One ICU You’ve Seen All ICUs: Evidence-based Recommendations for the Organization of Critical CareGordon D. Rubenfeld, MD, MS
- Edward C. Rosenow III, MD, Master FCCP/Master Teacher Honor Lecture “Pills” and the Air PassagesAtul C. Mehta, MBBS, FCCP
- Murray Kornfeld Memorial Founders Lecture Trying to Change Clinical Practice: The Barcelona Respiratory Research GroupAntonio Torres Marti, MD, PhD, FCCP
CHEST Foundation Grant Awards
- CHEST Foundation Research Grant in Nontuberculous Mycobacteria Keira Cohen, MD
- CHEST Foundation and the Alpha-1 Foundation Research Grant in Alpha-1 Antitrypsin Deficiency Diana Crossley, MBChB
- CHEST Foundation Research Grant in Asthma Drew Harris, MD
- CHEST Foundation Research Grant in Pulmonary Fibrosis Kerri Johannson, MD, MPH
- CHEST Foundation Research Grant in Women’s Lung Health Stephen Lapinsky, MBBCh, MS
- CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease Emmet O’Brien, MBBCh
- CHEST Foundation Research Grant in Venous Thromboembolism Christopher Pannucci, MD
- CHEST Foundation Research Grant in Cystic Fibrosis Kathleen Ramos, MD, MS
- CHEST Foundation Research Grant in Pulmonary Arterial Hypertension Sandeep Sahay, MD, FCCP
- CHEST Foundation Research Grant in Lung Cancer Kei Suzuki, MD
- GlaxoSmithKline Distinguished Scholar in Respiratory Health Richard Wunderlink, MD, FCCP
- CHEST Co-Branded Community Service Initiatives Sandra Adams, MD, MS, FCCP; Mary Hart, RRT, MS, FCCP
- GAIN NSCLC Summits Community Service Grant J. Scott Ferguson, MD, FCCP
- CHEST Foundation Community Service Grants Honoring D. Robert McCaffree, MD, Master FCCP; Negin Hajizadeh, MD, MPH; Adam Silverman, MD
Case Report Poster Winners
Javier Ramos Rossy, MD
Bikash Bhattarai, MD
Nikita Leiter, MD
Lindsay Boole, MD, MPH
Muhammad Hammami, MD
Jonathan Dewald, MD
Ahmed Mahgoub, MD
Ali Saeed, MD
Aditya Kotecha, MD
David Attalla, MD
CHEST Challenge Winners
San Antonio Military Medical Center
David Anderson, DO
Paul Hiles, MD, BSc
Tyson Sjulin, DO
Alfred Soffer Research Award Winners
- Marcos Restrepo, MD, MSc, FCCP: Anti-MRSA Coverage Overutilization as Empiric Therapy for Hospitalized Patients With Community-acquired Pneumonia and Health-care Associated Pneumonia
- Michael Perkins, MD: Rothman Index Predicts ICU Mortality at 24 hours
Young Investigator Award Winners
- Adam Przebinda, MD: Analysis of a Hospital-based Multimodal Quality Improvement Intervention to Improve Recognition and Treatment of Sepsis
- Roozehra Khan, DO, FCCP: Growth in Social Media & Live-Tweeting at Major Critical Care Conferences: Twitter Analysis of Past 4 Years
Top 5 Slide Presentation Winners
- Jonathan Corren, MD: Dupilumab Improves Asthma Control and Asthma-Related Quality of Life in Uncontrolled Persistent Asthma Patients Across All Baseline Exacerbation Rates
- Aaron B. Holley, MD, FCCP: Heparin prophylaxis does not prevent VTE in the presence of acute kidney injury
- Anil Vachani, MD, FCCP: A Blood-based Multi-gene Expression Classifier to Distinguish Benign from Malignant Pulmonary Nodules
- Abhishek Mishra, MD: Comparison of Catheter directed thrombolysis vs systemic thrombolysis in pulmonary embolism: A propensity score match analysis
- David E. Ost, MD, MPH, FCCP: Comparison of Practice Patterns and Outcomes for Recurrent Malignant Pleural Effusions
Case Report Slide Winners
- Christian Castaneda, MD: Levofloxacin-Induced Acute Eosinophilic Pneumonitis: A Case Report And Review
- Lucian Marts, MD: The Proof Is In The Platelets
- Fuad Aleskerov, MD: Disseminated Resistant Nocardiosis In Previously Healthy Male
- Taylor Myers, MD: Spontaneous Regression Of Non-Small Cell Lung Cancer
- Amin Pasha, MD: Is Fat Always Bad? A Case Study Demonstrating The Lifesaving Effect Of Lipid Emulsion Therapy In Beta Blocker And Calcium Channel Blocker Overdose
- Anish Geevarghese, MD: The Use Of Venovenous-ECMO For Refractory Hypoxemia Following Liver Transplantation In A Patient With Hepatopulmonary Syndrome
- Juilio Huapaya, MD: Hemophagocytic Lymphohistiocytosis Induced By Histoplasmosis In A Kidney Transplant Patient: Are Steroids Really Necessary?
- Stephen Doyle, DO, MBA: Diffuse Pulmonary Nodules: A Rare Infection Causing A Common Problem
- Catherine Millender, MD: An Intriguing Case Of Recurrent Bilateral Massive Chylothoraces: Is This Pleural Sarcoidosis?
- Andrew Lewis, DO: Transformation Of Benign Metastasizing Leiomyoma (BML) To Leiomyosarcoma
- Fady Youssef, MD: Tracheal Leiomyosarcoma Causing Critical Airway Obstruction
- Kevin Charles, MD: Pulmonary Metastasis Of Mandibular Amelobastoma: A Case Report
- Audra Fuller, MD: Endobronchial Lipomatous Hamartoma Mimicking Malignancy
- Lana Alghothani, MD: Idiopathic Pneumonia Syndrome In Patient With Gray Zone Lymphoma Successfully Treated With Etanercept
- Aaron Lampkin, MD: These Aren’t The Paraproteins You Have Been Looking For: A Case Of Light Chain Deposition Disease
- Tyler Church: His Heart Was Three Sizes Too Smallpox
- Ki-Yoon Kim, MD: Coma Secondary To Rickettsia Typhi
- Nicole Ruopp, MD: Epoprostenol And Ascites: A High Output State Or Not?
- Stephanie Guo, MD: Neuroendocrine Cells And A Spectrum Of Disease
- Justin Chiam, MBBS: A Diagnostic Challenge Of Haemoptysis In A TB Endemic Southeast Asian Country
NetWork Challenge Winners
- First Round: Home-Based Mechanical Ventilation and Neuromuscular Disease NetWork, and Women’s Health NetWork
- Second Round:Home-Based Mechanical Ventilation and Neuromuscular Disease and Practice Operations
- Third Round: Home-Based Mechanical Ventilation and Neuromuscular Disease and Practice Operations
With the great success of CHEST 2017, everyone who shared that event is a winner. But, we would especially like to call out some of the special winners who were recognized during our meeting in Toronto.
CHEST 2017 Awards
- College Medalist Award Sidney Braman, MD, Master FCCP
- Distinguished Service Award Nancy Collop, MD, FCCP
- Master FCCP Suhail Raoof, MD, Master FCCP
- Master FCCP Sidney Braman, MD, Master FCCP
- Early Career Clinician Educator Septimiu Murgu, MD, FCCP
- Master Clinician Educator Stephanie Levine, MD, FCCP
- Presidential Citation Sanjeev Mehta, MD, FCCP
- Presidential Citation Lisa Moores, MD, FCCP
- Alfred Soffer Award for Editorial Excellence Christopher Carroll, MD, FCCPDeep Ramachandran, MBBS
Honor Lectures
- Thomas L. Petty, MD, Master FCCP Memorial Lecture Personalized Treatment in COPD: A New Era of Treatment OptionsGerard J. Criner, MD, FCCP
- Presidential Honor Lecture Passion, Perseverance, and Quantum Leaps: Major Advances in Lung Cancer CareM. Patricia Rivera, MD, FCCP
- Margaret Pfrommer Memorial Lecture in Long-term Mechanical Ventilation When Air becomes BREATH…and a LIFE worth living Audrey King, MA
- Distinguished Scientist Honor Lecture in Cardiopulmonary Physiology Sleep, Death and the HeartVirend K. Somers, MD, PhD, FCCP
- Pasquale Ciaglia Memorial Lecture in Interventional Medicine Augmented Reality: Getting Real in Procedural EducationCarla R. Lamb, MD, FCCP
- Roger C. Bone Memorial Lecture in Critical Care If You’ve Seen One ICU You’ve Seen All ICUs: Evidence-based Recommendations for the Organization of Critical CareGordon D. Rubenfeld, MD, MS
- Edward C. Rosenow III, MD, Master FCCP/Master Teacher Honor Lecture “Pills” and the Air PassagesAtul C. Mehta, MBBS, FCCP
- Murray Kornfeld Memorial Founders Lecture Trying to Change Clinical Practice: The Barcelona Respiratory Research GroupAntonio Torres Marti, MD, PhD, FCCP
CHEST Foundation Grant Awards
- CHEST Foundation Research Grant in Nontuberculous Mycobacteria Keira Cohen, MD
- CHEST Foundation and the Alpha-1 Foundation Research Grant in Alpha-1 Antitrypsin Deficiency Diana Crossley, MBChB
- CHEST Foundation Research Grant in Asthma Drew Harris, MD
- CHEST Foundation Research Grant in Pulmonary Fibrosis Kerri Johannson, MD, MPH
- CHEST Foundation Research Grant in Women’s Lung Health Stephen Lapinsky, MBBCh, MS
- CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease Emmet O’Brien, MBBCh
- CHEST Foundation Research Grant in Venous Thromboembolism Christopher Pannucci, MD
- CHEST Foundation Research Grant in Cystic Fibrosis Kathleen Ramos, MD, MS
- CHEST Foundation Research Grant in Pulmonary Arterial Hypertension Sandeep Sahay, MD, FCCP
- CHEST Foundation Research Grant in Lung Cancer Kei Suzuki, MD
- GlaxoSmithKline Distinguished Scholar in Respiratory Health Richard Wunderlink, MD, FCCP
- CHEST Co-Branded Community Service Initiatives Sandra Adams, MD, MS, FCCP; Mary Hart, RRT, MS, FCCP
- GAIN NSCLC Summits Community Service Grant J. Scott Ferguson, MD, FCCP
- CHEST Foundation Community Service Grants Honoring D. Robert McCaffree, MD, Master FCCP; Negin Hajizadeh, MD, MPH; Adam Silverman, MD
Case Report Poster Winners
Javier Ramos Rossy, MD
Bikash Bhattarai, MD
Nikita Leiter, MD
Lindsay Boole, MD, MPH
Muhammad Hammami, MD
Jonathan Dewald, MD
Ahmed Mahgoub, MD
Ali Saeed, MD
Aditya Kotecha, MD
David Attalla, MD
CHEST Challenge Winners
San Antonio Military Medical Center
David Anderson, DO
Paul Hiles, MD, BSc
Tyson Sjulin, DO
Alfred Soffer Research Award Winners
- Marcos Restrepo, MD, MSc, FCCP: Anti-MRSA Coverage Overutilization as Empiric Therapy for Hospitalized Patients With Community-acquired Pneumonia and Health-care Associated Pneumonia
- Michael Perkins, MD: Rothman Index Predicts ICU Mortality at 24 hours
Young Investigator Award Winners
- Adam Przebinda, MD: Analysis of a Hospital-based Multimodal Quality Improvement Intervention to Improve Recognition and Treatment of Sepsis
- Roozehra Khan, DO, FCCP: Growth in Social Media & Live-Tweeting at Major Critical Care Conferences: Twitter Analysis of Past 4 Years
Top 5 Slide Presentation Winners
- Jonathan Corren, MD: Dupilumab Improves Asthma Control and Asthma-Related Quality of Life in Uncontrolled Persistent Asthma Patients Across All Baseline Exacerbation Rates
- Aaron B. Holley, MD, FCCP: Heparin prophylaxis does not prevent VTE in the presence of acute kidney injury
- Anil Vachani, MD, FCCP: A Blood-based Multi-gene Expression Classifier to Distinguish Benign from Malignant Pulmonary Nodules
- Abhishek Mishra, MD: Comparison of Catheter directed thrombolysis vs systemic thrombolysis in pulmonary embolism: A propensity score match analysis
- David E. Ost, MD, MPH, FCCP: Comparison of Practice Patterns and Outcomes for Recurrent Malignant Pleural Effusions
Case Report Slide Winners
- Christian Castaneda, MD: Levofloxacin-Induced Acute Eosinophilic Pneumonitis: A Case Report And Review
- Lucian Marts, MD: The Proof Is In The Platelets
- Fuad Aleskerov, MD: Disseminated Resistant Nocardiosis In Previously Healthy Male
- Taylor Myers, MD: Spontaneous Regression Of Non-Small Cell Lung Cancer
- Amin Pasha, MD: Is Fat Always Bad? A Case Study Demonstrating The Lifesaving Effect Of Lipid Emulsion Therapy In Beta Blocker And Calcium Channel Blocker Overdose
- Anish Geevarghese, MD: The Use Of Venovenous-ECMO For Refractory Hypoxemia Following Liver Transplantation In A Patient With Hepatopulmonary Syndrome
- Juilio Huapaya, MD: Hemophagocytic Lymphohistiocytosis Induced By Histoplasmosis In A Kidney Transplant Patient: Are Steroids Really Necessary?
- Stephen Doyle, DO, MBA: Diffuse Pulmonary Nodules: A Rare Infection Causing A Common Problem
- Catherine Millender, MD: An Intriguing Case Of Recurrent Bilateral Massive Chylothoraces: Is This Pleural Sarcoidosis?
- Andrew Lewis, DO: Transformation Of Benign Metastasizing Leiomyoma (BML) To Leiomyosarcoma
- Fady Youssef, MD: Tracheal Leiomyosarcoma Causing Critical Airway Obstruction
- Kevin Charles, MD: Pulmonary Metastasis Of Mandibular Amelobastoma: A Case Report
- Audra Fuller, MD: Endobronchial Lipomatous Hamartoma Mimicking Malignancy
- Lana Alghothani, MD: Idiopathic Pneumonia Syndrome In Patient With Gray Zone Lymphoma Successfully Treated With Etanercept
- Aaron Lampkin, MD: These Aren’t The Paraproteins You Have Been Looking For: A Case Of Light Chain Deposition Disease
- Tyler Church: His Heart Was Three Sizes Too Smallpox
- Ki-Yoon Kim, MD: Coma Secondary To Rickettsia Typhi
- Nicole Ruopp, MD: Epoprostenol And Ascites: A High Output State Or Not?
- Stephanie Guo, MD: Neuroendocrine Cells And A Spectrum Of Disease
- Justin Chiam, MBBS: A Diagnostic Challenge Of Haemoptysis In A TB Endemic Southeast Asian Country
NetWork Challenge Winners
- First Round: Home-Based Mechanical Ventilation and Neuromuscular Disease NetWork, and Women’s Health NetWork
- Second Round:Home-Based Mechanical Ventilation and Neuromuscular Disease and Practice Operations
- Third Round: Home-Based Mechanical Ventilation and Neuromuscular Disease and Practice Operations
With the great success of CHEST 2017, everyone who shared that event is a winner. But, we would especially like to call out some of the special winners who were recognized during our meeting in Toronto.
CHEST 2017 Awards
- College Medalist Award Sidney Braman, MD, Master FCCP
- Distinguished Service Award Nancy Collop, MD, FCCP
- Master FCCP Suhail Raoof, MD, Master FCCP
- Master FCCP Sidney Braman, MD, Master FCCP
- Early Career Clinician Educator Septimiu Murgu, MD, FCCP
- Master Clinician Educator Stephanie Levine, MD, FCCP
- Presidential Citation Sanjeev Mehta, MD, FCCP
- Presidential Citation Lisa Moores, MD, FCCP
- Alfred Soffer Award for Editorial Excellence Christopher Carroll, MD, FCCPDeep Ramachandran, MBBS
Honor Lectures
- Thomas L. Petty, MD, Master FCCP Memorial Lecture Personalized Treatment in COPD: A New Era of Treatment OptionsGerard J. Criner, MD, FCCP
- Presidential Honor Lecture Passion, Perseverance, and Quantum Leaps: Major Advances in Lung Cancer CareM. Patricia Rivera, MD, FCCP
- Margaret Pfrommer Memorial Lecture in Long-term Mechanical Ventilation When Air becomes BREATH…and a LIFE worth living Audrey King, MA
- Distinguished Scientist Honor Lecture in Cardiopulmonary Physiology Sleep, Death and the HeartVirend K. Somers, MD, PhD, FCCP
- Pasquale Ciaglia Memorial Lecture in Interventional Medicine Augmented Reality: Getting Real in Procedural EducationCarla R. Lamb, MD, FCCP
- Roger C. Bone Memorial Lecture in Critical Care If You’ve Seen One ICU You’ve Seen All ICUs: Evidence-based Recommendations for the Organization of Critical CareGordon D. Rubenfeld, MD, MS
- Edward C. Rosenow III, MD, Master FCCP/Master Teacher Honor Lecture “Pills” and the Air PassagesAtul C. Mehta, MBBS, FCCP
- Murray Kornfeld Memorial Founders Lecture Trying to Change Clinical Practice: The Barcelona Respiratory Research GroupAntonio Torres Marti, MD, PhD, FCCP
CHEST Foundation Grant Awards
- CHEST Foundation Research Grant in Nontuberculous Mycobacteria Keira Cohen, MD
- CHEST Foundation and the Alpha-1 Foundation Research Grant in Alpha-1 Antitrypsin Deficiency Diana Crossley, MBChB
- CHEST Foundation Research Grant in Asthma Drew Harris, MD
- CHEST Foundation Research Grant in Pulmonary Fibrosis Kerri Johannson, MD, MPH
- CHEST Foundation Research Grant in Women’s Lung Health Stephen Lapinsky, MBBCh, MS
- CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease Emmet O’Brien, MBBCh
- CHEST Foundation Research Grant in Venous Thromboembolism Christopher Pannucci, MD
- CHEST Foundation Research Grant in Cystic Fibrosis Kathleen Ramos, MD, MS
- CHEST Foundation Research Grant in Pulmonary Arterial Hypertension Sandeep Sahay, MD, FCCP
- CHEST Foundation Research Grant in Lung Cancer Kei Suzuki, MD
- GlaxoSmithKline Distinguished Scholar in Respiratory Health Richard Wunderlink, MD, FCCP
- CHEST Co-Branded Community Service Initiatives Sandra Adams, MD, MS, FCCP; Mary Hart, RRT, MS, FCCP
- GAIN NSCLC Summits Community Service Grant J. Scott Ferguson, MD, FCCP
- CHEST Foundation Community Service Grants Honoring D. Robert McCaffree, MD, Master FCCP; Negin Hajizadeh, MD, MPH; Adam Silverman, MD
Case Report Poster Winners
Javier Ramos Rossy, MD
Bikash Bhattarai, MD
Nikita Leiter, MD
Lindsay Boole, MD, MPH
Muhammad Hammami, MD
Jonathan Dewald, MD
Ahmed Mahgoub, MD
Ali Saeed, MD
Aditya Kotecha, MD
David Attalla, MD
CHEST Challenge Winners
San Antonio Military Medical Center
David Anderson, DO
Paul Hiles, MD, BSc
Tyson Sjulin, DO
Alfred Soffer Research Award Winners
- Marcos Restrepo, MD, MSc, FCCP: Anti-MRSA Coverage Overutilization as Empiric Therapy for Hospitalized Patients With Community-acquired Pneumonia and Health-care Associated Pneumonia
- Michael Perkins, MD: Rothman Index Predicts ICU Mortality at 24 hours
Young Investigator Award Winners
- Adam Przebinda, MD: Analysis of a Hospital-based Multimodal Quality Improvement Intervention to Improve Recognition and Treatment of Sepsis
- Roozehra Khan, DO, FCCP: Growth in Social Media & Live-Tweeting at Major Critical Care Conferences: Twitter Analysis of Past 4 Years
Top 5 Slide Presentation Winners
- Jonathan Corren, MD: Dupilumab Improves Asthma Control and Asthma-Related Quality of Life in Uncontrolled Persistent Asthma Patients Across All Baseline Exacerbation Rates
- Aaron B. Holley, MD, FCCP: Heparin prophylaxis does not prevent VTE in the presence of acute kidney injury
- Anil Vachani, MD, FCCP: A Blood-based Multi-gene Expression Classifier to Distinguish Benign from Malignant Pulmonary Nodules
- Abhishek Mishra, MD: Comparison of Catheter directed thrombolysis vs systemic thrombolysis in pulmonary embolism: A propensity score match analysis
- David E. Ost, MD, MPH, FCCP: Comparison of Practice Patterns and Outcomes for Recurrent Malignant Pleural Effusions
Case Report Slide Winners
- Christian Castaneda, MD: Levofloxacin-Induced Acute Eosinophilic Pneumonitis: A Case Report And Review
- Lucian Marts, MD: The Proof Is In The Platelets
- Fuad Aleskerov, MD: Disseminated Resistant Nocardiosis In Previously Healthy Male
- Taylor Myers, MD: Spontaneous Regression Of Non-Small Cell Lung Cancer
- Amin Pasha, MD: Is Fat Always Bad? A Case Study Demonstrating The Lifesaving Effect Of Lipid Emulsion Therapy In Beta Blocker And Calcium Channel Blocker Overdose
- Anish Geevarghese, MD: The Use Of Venovenous-ECMO For Refractory Hypoxemia Following Liver Transplantation In A Patient With Hepatopulmonary Syndrome
- Juilio Huapaya, MD: Hemophagocytic Lymphohistiocytosis Induced By Histoplasmosis In A Kidney Transplant Patient: Are Steroids Really Necessary?
- Stephen Doyle, DO, MBA: Diffuse Pulmonary Nodules: A Rare Infection Causing A Common Problem
- Catherine Millender, MD: An Intriguing Case Of Recurrent Bilateral Massive Chylothoraces: Is This Pleural Sarcoidosis?
- Andrew Lewis, DO: Transformation Of Benign Metastasizing Leiomyoma (BML) To Leiomyosarcoma
- Fady Youssef, MD: Tracheal Leiomyosarcoma Causing Critical Airway Obstruction
- Kevin Charles, MD: Pulmonary Metastasis Of Mandibular Amelobastoma: A Case Report
- Audra Fuller, MD: Endobronchial Lipomatous Hamartoma Mimicking Malignancy
- Lana Alghothani, MD: Idiopathic Pneumonia Syndrome In Patient With Gray Zone Lymphoma Successfully Treated With Etanercept
- Aaron Lampkin, MD: These Aren’t The Paraproteins You Have Been Looking For: A Case Of Light Chain Deposition Disease
- Tyler Church: His Heart Was Three Sizes Too Smallpox
- Ki-Yoon Kim, MD: Coma Secondary To Rickettsia Typhi
- Nicole Ruopp, MD: Epoprostenol And Ascites: A High Output State Or Not?
- Stephanie Guo, MD: Neuroendocrine Cells And A Spectrum Of Disease
- Justin Chiam, MBBS: A Diagnostic Challenge Of Haemoptysis In A TB Endemic Southeast Asian Country
NetWork Challenge Winners
- First Round: Home-Based Mechanical Ventilation and Neuromuscular Disease NetWork, and Women’s Health NetWork
- Second Round:Home-Based Mechanical Ventilation and Neuromuscular Disease and Practice Operations
- Third Round: Home-Based Mechanical Ventilation and Neuromuscular Disease and Practice Operations
Endovenous thermal ablation and thrombotic complications
“CLINICAL CORRELATION OF SUCCESS AND ACUTE THROMBOTIC COMPLICATIONS OF LOWER EXTREMITY ENDOVENOUS THERMAL ABLATION.” Journal of Vascular Surgery Venous and Lymphatic Disorders, January 2018
A large single center experience with endovenous thermal ablation reveals risk factors for thrombotic complications.
Minimally invasive techniques for treating reflux disease in the saphenous system have greatly improved the quality of life and comfort of those suffering with chronic venous disease and more advanced venous insufficiency. Painful procedures of the past, sometimes including hospital stays, have largely been replaced by safe and efficacious office procedures (lasting often less than an hour) with minimal subsequent activity restrictions.
Despite these obvious advantages, these therapies do have a very low but definite risk of thrombotic complications, including endovenous heat-induced thrombosis (EHIT) superficial venous thrombosis (SVT) and deep vein thrombosis (DVT). EHIT includes development of a blood clot at the junction of one of the treated saphenous veins and the femoral or the popliteal vein.
While major DVT and pulmonary embolism are extremely rare, the diagnosis of EHIT may require a period of anticoagulation as well as follow-up visits and studies. Further, acute SVT can be painful for several weeks following the procedure. As such, further understanding the risk factors for these complications will allow therapists to better inform patients as to their specific risks for developing them.
As reported in the January 2018 edition of the Journal of Vascular Surgery: Venous and Lymphatic Disorders, researchers from Total Vascular Care and NYU Lutheran Medical Center led by Afsha Aurshina, MBBS, evaluated their large single center experience treating multiple vein types using both radiofrequency (RFA) and endovenous laser (EVLA) ablation techniques. They retrospectively studied the outcomes of 1811 procedures performed on 808 patients from 2012-2014. The aim of the study was to define better the success and thrombotic complications of these procedures with respect to technique and vein type.
Overall success (defined as absence of reflux in the targeted vein by post-operative duplex) rates included:
- RFA 98.4% (excluding perforating vein)
- EVLA 98.1%
- Great saphenous (GSV) 98.5%
- Lesser saphenous (LSV) 98.2%
- Accessory saphenous (ASV) 97.2%
- Perforator (PV) 82.4%
With regards to thrombotic complications, the authors reported EHIT rates of:
- Class 1-4 5.9%
- Class 2-4 1.16%
Acute superficial thrombosis rates included:
- Overall 4.6%
- RFA 7.7%
- EVLA 11.4% (no difference in multi-factor analysis)
- GSV 11.8%
- LSV 5.5%
- ASV 6.5%
- PV 2.4%
“Our study demonstrates that there is no significant difference in the success rate of RFA and EVLA in the treatment of venous reflux for GSV, SSV, and ASV,” notes first author Aurshina. “We found an acceptably low incidence of clinically significant thrombotic complication rates for EHIT and acute superficial thrombosis, with only a 1.16% risk of Class 2-4 EHIT, that may require short term anticoagulation. We noted risk factors for these complications, after multi-factor analysis, include higher vein diameter and type of vein, with the latter being the most important.”
Large experiences such as these are important to understand the true incidence of these complications and how practitioners might tailor their consent process with their patients.
To download the complete article (link available free from 12/14/2017 through 2/28/2018),
click: http://vsweb.org/JVSVL-EVTA
For information your patients may be interested in, click:
Regarding Varicose Veins:
https://vascular.org/patient-resources/vascular-conditions/varicose-veins
Regarding Deep Venous Thrombosis:
https://vascular.org/patient-resources/vascular-conditions/deep-vein-thrombosis
“CLINICAL CORRELATION OF SUCCESS AND ACUTE THROMBOTIC COMPLICATIONS OF LOWER EXTREMITY ENDOVENOUS THERMAL ABLATION.” Journal of Vascular Surgery Venous and Lymphatic Disorders, January 2018
A large single center experience with endovenous thermal ablation reveals risk factors for thrombotic complications.
Minimally invasive techniques for treating reflux disease in the saphenous system have greatly improved the quality of life and comfort of those suffering with chronic venous disease and more advanced venous insufficiency. Painful procedures of the past, sometimes including hospital stays, have largely been replaced by safe and efficacious office procedures (lasting often less than an hour) with minimal subsequent activity restrictions.
Despite these obvious advantages, these therapies do have a very low but definite risk of thrombotic complications, including endovenous heat-induced thrombosis (EHIT) superficial venous thrombosis (SVT) and deep vein thrombosis (DVT). EHIT includes development of a blood clot at the junction of one of the treated saphenous veins and the femoral or the popliteal vein.
While major DVT and pulmonary embolism are extremely rare, the diagnosis of EHIT may require a period of anticoagulation as well as follow-up visits and studies. Further, acute SVT can be painful for several weeks following the procedure. As such, further understanding the risk factors for these complications will allow therapists to better inform patients as to their specific risks for developing them.
As reported in the January 2018 edition of the Journal of Vascular Surgery: Venous and Lymphatic Disorders, researchers from Total Vascular Care and NYU Lutheran Medical Center led by Afsha Aurshina, MBBS, evaluated their large single center experience treating multiple vein types using both radiofrequency (RFA) and endovenous laser (EVLA) ablation techniques. They retrospectively studied the outcomes of 1811 procedures performed on 808 patients from 2012-2014. The aim of the study was to define better the success and thrombotic complications of these procedures with respect to technique and vein type.
Overall success (defined as absence of reflux in the targeted vein by post-operative duplex) rates included:
- RFA 98.4% (excluding perforating vein)
- EVLA 98.1%
- Great saphenous (GSV) 98.5%
- Lesser saphenous (LSV) 98.2%
- Accessory saphenous (ASV) 97.2%
- Perforator (PV) 82.4%
With regards to thrombotic complications, the authors reported EHIT rates of:
- Class 1-4 5.9%
- Class 2-4 1.16%
Acute superficial thrombosis rates included:
- Overall 4.6%
- RFA 7.7%
- EVLA 11.4% (no difference in multi-factor analysis)
- GSV 11.8%
- LSV 5.5%
- ASV 6.5%
- PV 2.4%
“Our study demonstrates that there is no significant difference in the success rate of RFA and EVLA in the treatment of venous reflux for GSV, SSV, and ASV,” notes first author Aurshina. “We found an acceptably low incidence of clinically significant thrombotic complication rates for EHIT and acute superficial thrombosis, with only a 1.16% risk of Class 2-4 EHIT, that may require short term anticoagulation. We noted risk factors for these complications, after multi-factor analysis, include higher vein diameter and type of vein, with the latter being the most important.”
Large experiences such as these are important to understand the true incidence of these complications and how practitioners might tailor their consent process with their patients.
To download the complete article (link available free from 12/14/2017 through 2/28/2018),
click: http://vsweb.org/JVSVL-EVTA
For information your patients may be interested in, click:
Regarding Varicose Veins:
https://vascular.org/patient-resources/vascular-conditions/varicose-veins
Regarding Deep Venous Thrombosis:
https://vascular.org/patient-resources/vascular-conditions/deep-vein-thrombosis
“CLINICAL CORRELATION OF SUCCESS AND ACUTE THROMBOTIC COMPLICATIONS OF LOWER EXTREMITY ENDOVENOUS THERMAL ABLATION.” Journal of Vascular Surgery Venous and Lymphatic Disorders, January 2018
A large single center experience with endovenous thermal ablation reveals risk factors for thrombotic complications.
Minimally invasive techniques for treating reflux disease in the saphenous system have greatly improved the quality of life and comfort of those suffering with chronic venous disease and more advanced venous insufficiency. Painful procedures of the past, sometimes including hospital stays, have largely been replaced by safe and efficacious office procedures (lasting often less than an hour) with minimal subsequent activity restrictions.
Despite these obvious advantages, these therapies do have a very low but definite risk of thrombotic complications, including endovenous heat-induced thrombosis (EHIT) superficial venous thrombosis (SVT) and deep vein thrombosis (DVT). EHIT includes development of a blood clot at the junction of one of the treated saphenous veins and the femoral or the popliteal vein.
While major DVT and pulmonary embolism are extremely rare, the diagnosis of EHIT may require a period of anticoagulation as well as follow-up visits and studies. Further, acute SVT can be painful for several weeks following the procedure. As such, further understanding the risk factors for these complications will allow therapists to better inform patients as to their specific risks for developing them.
As reported in the January 2018 edition of the Journal of Vascular Surgery: Venous and Lymphatic Disorders, researchers from Total Vascular Care and NYU Lutheran Medical Center led by Afsha Aurshina, MBBS, evaluated their large single center experience treating multiple vein types using both radiofrequency (RFA) and endovenous laser (EVLA) ablation techniques. They retrospectively studied the outcomes of 1811 procedures performed on 808 patients from 2012-2014. The aim of the study was to define better the success and thrombotic complications of these procedures with respect to technique and vein type.
Overall success (defined as absence of reflux in the targeted vein by post-operative duplex) rates included:
- RFA 98.4% (excluding perforating vein)
- EVLA 98.1%
- Great saphenous (GSV) 98.5%
- Lesser saphenous (LSV) 98.2%
- Accessory saphenous (ASV) 97.2%
- Perforator (PV) 82.4%
With regards to thrombotic complications, the authors reported EHIT rates of:
- Class 1-4 5.9%
- Class 2-4 1.16%
Acute superficial thrombosis rates included:
- Overall 4.6%
- RFA 7.7%
- EVLA 11.4% (no difference in multi-factor analysis)
- GSV 11.8%
- LSV 5.5%
- ASV 6.5%
- PV 2.4%
“Our study demonstrates that there is no significant difference in the success rate of RFA and EVLA in the treatment of venous reflux for GSV, SSV, and ASV,” notes first author Aurshina. “We found an acceptably low incidence of clinically significant thrombotic complication rates for EHIT and acute superficial thrombosis, with only a 1.16% risk of Class 2-4 EHIT, that may require short term anticoagulation. We noted risk factors for these complications, after multi-factor analysis, include higher vein diameter and type of vein, with the latter being the most important.”
Large experiences such as these are important to understand the true incidence of these complications and how practitioners might tailor their consent process with their patients.
To download the complete article (link available free from 12/14/2017 through 2/28/2018),
click: http://vsweb.org/JVSVL-EVTA
For information your patients may be interested in, click:
Regarding Varicose Veins:
https://vascular.org/patient-resources/vascular-conditions/varicose-veins
Regarding Deep Venous Thrombosis:
https://vascular.org/patient-resources/vascular-conditions/deep-vein-thrombosis
Register for VRIC; Abstracts due Jan. 10
Registration is now open for the Vascular Research Initiatives Conference, to be held Thursday, May 9, in San Francisco. Abstracts for VRIC are due Wednesday, Jan. 10. Learn more about VRIC, and submit your abstracts here.
Registration is now open for the Vascular Research Initiatives Conference, to be held Thursday, May 9, in San Francisco. Abstracts for VRIC are due Wednesday, Jan. 10. Learn more about VRIC, and submit your abstracts here.
Registration is now open for the Vascular Research Initiatives Conference, to be held Thursday, May 9, in San Francisco. Abstracts for VRIC are due Wednesday, Jan. 10. Learn more about VRIC, and submit your abstracts here.